BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9586087)

  • 1. Specific RNA aptamers to NS3 protease domain of hepatitis C virus.
    Fukuda K; Vishinuvardhan D; Sekiya S; Kakiuchi N; Shimotohno K; Kumar PK; Nishikawa S
    Nucleic Acids Symp Ser; 1997; (37):237-8. PubMed ID: 9586087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RNA aptamer-binding site of hepatitis C virus NS3 protease.
    Hwang J; Fauzi H; Fukuda K; Sekiya S; Kakiuchi N; Shimotohno K; Taira K; Kusakabe I; Nishikawa S
    Biochem Biophys Res Commun; 2000 Dec; 279(2):557-62. PubMed ID: 11118325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA.
    Kumar PK; Machida K; Urvil PT; Kakiuchi N; Vishnuvardhan D; Shimotohno K; Taira K; Nishikawa S
    Virology; 1997 Oct; 237(2):270-82. PubMed ID: 9356339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
    Thibeault D; Massariol MJ; Zhao S; Welchner E; Goudreau N; Gingras R; Llinàs-Brunet M; White PW
    Biochemistry; 2009 Feb; 48(4):744-53. PubMed ID: 19119853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3.
    Umehara T; Fukuda K; Nishikawa F; Sekiya S; Kohara M; Hasegawa T; Nishikawa S
    Nucleic Acids Symp Ser (Oxf); 2004; (48):195-6. PubMed ID: 17150545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational design of dual-functional aptamers that inhibit the protease and helicase activities of HCV NS3.
    Umehara T; Fukuda K; Nishikawa F; Kohara M; Hasegawa T; Nishikawa S
    J Biochem; 2005 Mar; 137(3):339-47. PubMed ID: 15809335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of substrate specificity of hepatitis G virus NS3 protease by a genetic method.
    Lee YJ; Kang H; Rho SH; Eom SH; Park WJ
    Biochem Biophys Res Commun; 2001 Aug; 286(1):171-5. PubMed ID: 11485324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of RNA binding activity and RNA helicase activity of the hepatitis C virus NS3 protein.
    Gwack Y; Kim DW; Han JH; Choe J
    Biochem Biophys Res Commun; 1996 Aug; 225(2):654-9. PubMed ID: 8753814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease.
    Fukuda K; Vishnuvardhan D; Sekiya S; Hwang J; Kakiuchi N; Taira K; Shimotohno K; Kumar PK; Nishikawa S
    Eur J Biochem; 2000 Jun; 267(12):3685-94. PubMed ID: 10848986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An RNA ligand inhibits hepatitis C virus NS3 protease and helicase activities.
    Fukuda K; Umehara T; Sekiya S; Kunio K; Hasegawa T; Nishikawa S
    Biochem Biophys Res Commun; 2004 Dec; 325(3):670-5. PubMed ID: 15541341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Product inhibition of the hepatitis C virus NS3 protease.
    Steinkühler C; Biasiol G; Brunetti M; Urbani A; Koch U; Cortese R; Pessi A; De Francesco R
    Biochemistry; 1998 Jun; 37(25):8899-905. PubMed ID: 9636031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of RNA aptamers that bind specifically to the NS3 protease of hepatitis C virus.
    Urvil PT; Kakiuchi N; Zhou DM; Shimotohno K; Kumar PK; Nishikawa S
    Eur J Biochem; 1997 Aug; 248(1):130-8. PubMed ID: 9310370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hepatitis C virus NS3 proteinase: structure and function of a zinc-containing serine proteinase.
    De Francesco R; Pessi A; Steinkühler C
    Antivir Ther; 1998; 3(Suppl 3):99-109. PubMed ID: 10726060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of the dual-functional RNA ligand against HCV NS3 protease and helicase.
    Fukuda K; Sekiya S; Kikuchi K; Funaji K; Kuno A; Hasegawa T; Nishikawa S
    Nucleic Acids Res Suppl; 2001; (1):147-8. PubMed ID: 12836307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A.
    Gallinari P; Paolini C; Brennan D; Nardi C; Steinkühler C; De Francesco R
    Biochemistry; 1999 Apr; 38(17):5620-32. PubMed ID: 10220351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solution structure and backbone dynamics of an engineered arginine-rich subdomain 2 of the hepatitis C virus NS3 RNA helicase.
    Liu D; Wang YS; Gesell JJ; Wyss DF
    J Mol Biol; 2001 Nov; 314(3):543-61. PubMed ID: 11846566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical point mutations for hepatitis C virus NS3 proteinase.
    Yamada K; Mori A; Seki M; Kimura J; Yuasa S; Matsuura Y; Miyamura T
    Virology; 1998 Jun; 246(1):104-12. PubMed ID: 9656998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solution structure and dynamics of the single-chain hepatitis C virus NS3 protease NS4A cofactor complex.
    McCoy MA; Senior MM; Gesell JJ; Ramanathan L; Wyss DF
    J Mol Biol; 2001 Feb; 305(5):1099-110. PubMed ID: 11162117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen.
    Gal-Tanamy M; Zemel R; Berdichevsky Y; Bachmatov L; Tur-Kaspa R; Benhar I
    J Mol Biol; 2005 Apr; 347(5):991-1003. PubMed ID: 15784258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Internal processing of hepatitis C virus NS3 protein.
    Shoji I; Suzuki T; Sato M; Aizaki H; Chiba T; Matsuura Y; Miyamura T
    Virology; 1999 Feb; 254(2):315-23. PubMed ID: 9986797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.